Navigation Links
Semler to Report Second Quarter 2014 Financial Results and Host Conference Call on July 25, 2014
Date:7/22/2014

PORTLAND, Ore., July 22, 2014 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR; "Semler"), an emerging medical risk assessment company that develops patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced that it will report second quarter 2014 financial results before the open of U.S. financial markets on July 25, 2014. Doug Murphy-Chutorian, M.D., chief executive officer of Semler will host a conference call at 11 a.m. EDT, July 25, 2014.

The conference call may be accessed by dialing 877-359-9508 for domestic callers and 224-357-2393 for international callers. Please specify to the operator that you would like to join the "Semler Second Quarter 2014 Financial Results Call, conference ID#: 78080334." The conference call will be archived on Semler's website at semlerscientific.com.

About Semler Scientific, Inc.:
Semler Scientific, Inc. is an emerging medical risk-assessment company.  Its mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services. Semler's first patented and U.S. Food and Drug Administration, or FDA, cleared product, is FloChec®. FloChec® is used in the office setting to allow providers to measure arterial blood flow in the extremities and is a useful tool for internists and primary care physicians for whom it was previously impractical to conduct blood flow measurements. FloChec® received FDA 510(k) clearance in February 2010, Semler began Beta testing in the third quarter of 2010, and Semler began commercially leasing FloChec® in January 2011. Semler closed the initial public offering of its common stock on Febr
'/>"/>

SOURCE Semler Scientific, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. At RSNA, DR Systems Will Exhibit RIS, Reporting, Peer Review Systems
11. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Mass. , July 30, 2015   ... solutions for the interpretation and analysis of genomic ... Matthew Fischer has joined the company as ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... capabilities to integrate, interpret, analyze and explore complex ...
(Date:7/30/2015)... 30, 2015 According to a ... Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, ... Clinical Trial), by End Users - Global Forecast to ... to reach USD 2,107.99 million by 2020 from USD ... Browse more than 75 ...
(Date:7/30/2015)... July 30, 2015   Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel flavor ... today reported financial results for the second quarter 2015. ... 2015, we remain on track to achieve our commercial ... Executive Officer of the Company. "Since our last quarterly ...
(Date:7/30/2015)... LOUIS, July 30, 2015 HIGHLIGHTS:Q2 ... in 2014) , Reported sales were $697 million ... 2014.  Sales grew organically by 8%, and changes in ... acquisitions increased sales by 1%. , By business ... in Applied and 11% in SAFC Commercial. , ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... 9:00 a.m. Eastern Time on March 16, 2009 ... (Nasdaq: UTHR ) announced today that, based ... and Drug Administration (FDA), the FDA,s pending regulatory review ... treprostinil) will likely extend beyond its originally anticipated April ...
... Pangu BioPharma to SpeakSAN DIEGO, March 16 aTyr ... and development of an entirely new class of natural ... that it will participate at the ChinaBio(R) Investor Forum ... Cai, Senior Vice President of Clinical Development a aTyr ...
... cutting net operating expenses by approximately 50% in 2009 CTI ... March 16 Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: ... fourth quarter and year ended December 31, 2008. Recent Events ... Met primary endpoint in the Phase ...
Cached Biology Technology:United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso) 2United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso) 3aTyr Pharma to Present at ChinaBio(R) Investor Forum in Hong Kong 2Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 2Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 3Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 4Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 5Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 6Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 7Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 8
(Date:7/8/2015)... SPRINGS, Florida , July 8, 2015 ... constantly evolving as this summer,s must have products such as ... in demand as popularity for biometrics based devices continues to ... are NXT-ID, Inc. (NASDAQ: NXTD ), Google Inc. (NASDAQ: ... Inc. (NYSE: FIT ), GoPro, Inc. (NASDAQ: GPRO ...
(Date:7/7/2015)... July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... growing mobile commerce market announces a revised version of one of ... commercial will air on CNBC in New York ... and San Francisco metro areas.    ... on Wocket,s ability to replace all the cards in your wallet ...
(Date:7/2/2015)... GOTHENBURG, Sweden , July 2, 2015 ... fingerprint sensors FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor ... is one of FPC,s distributors in Asia ... Q4 2015. The sensors will be used by smartphone manufacturers ... 268 MSEK is included in the communicated revenue guidance of ...
Breaking Biology News(10 mins):Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... , This release is available in French ... health. However, some people have inherited conditions that leave them ... prone to serious health problems, including developmental delay, psychosis, stroke ... genetic disease related to vitamin B12 deficiency by identifying a ...
... native vegetation offer birds "mini-refuges" and help to offset ... a study published today in the journal PLOS ... those with traditional grass lawns and non-native plantings. ... (NSF) Central Arizona-Phoenix Long-Term Ecological Research (LTER) site, one ...
... many reasons why it is important to be able to ... identification marks are essential for ensuring the correctness of breeding ... the possibility of deceit in competitions or when animals are ... relies on branding with hot irons or on ear-tagging but ...
Cached Biology News:Vitamin B12 deficiency: Tracking the genetic causes 2Native plants in urban yards offer birds 'mini-refuges' 2Native plants in urban yards offer birds 'mini-refuges' 3The end of an era? Branding horses does not enable them to be identified 2
IMAGEQUANT 100 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
IMAGEQUANT 300 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
Recombinant Feline IL-12/IL-23 p40 (C-Terminus), CF...
HybriWell™ hybridization sealing system, 20 mm diameter chamber, 0.15 mm deep *set of 100*...
Biology Products: